Sandbox:Hannan: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
standard
standard
Line 16: Line 16:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Imaging
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
!CT scan
!FDG PET/CT
!MRI
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adrenal adenoma|Adenoma]]
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adrenal adenoma|Adenoma]]
Line 47: Line 50:
** [[Zona fasciculata|ZG]] (small, compact [[cells]] with moderate amount of [[lipid]])
** [[Zona fasciculata|ZG]] (small, compact [[cells]] with moderate amount of [[lipid]])
** [[Zona reticularis|ZR]] (lipid-sparse [[cytoplasm]])
** [[Zona reticularis|ZR]] (lipid-sparse [[cytoplasm]])
|
* [[Adrenal]] [[mass]] or [[nodule]]
* Unilateral or bilateral [[adrenal]] [[atrophy]]
* Hypodense [[mass]] ([[CT]])
* Iso and low [[FDG]] uptake compared with [[liver]] ([[FDG]] [[PET]]/[[CT]])
* Hyperintense on in-phase and hypointense on oppose-phase ([[MRI]])
|
|
* [[Fludrocortisone]] suppression testing (Gold standard)
* [[Fludrocortisone]] suppression testing (Gold standard)
Line 63: Line 60:
* [[Immunohistochemical staining]]
* [[Immunohistochemical staining]]
*  
*  
|
* [[Adrenal]] [[mass]] or [[nodule]]
|
* [[nodule|Adrenal]] [[mass]] or nodule
* [[nodule|Unilateral or bilateral]] [[adrenal]] [[atrophy]]
* [[nodule|Hypodense]] [[mass]]
|
* Iso and low [[FDG]] uptake compared with [[liver]]
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
|
* [[Fludrocortisone]] suppression testing
* [[Fludrocortisone]] suppression testing
Line 106: Line 113:
* Adjacent [[Atrophy|atrophied]] [[cells]]
* Adjacent [[Atrophy|atrophied]] [[cells]]
* [[Hemorrhage]] and [[calcification]] (Pre-[[malignant]] [[lesions]])
* [[Hemorrhage]] and [[calcification]] (Pre-[[malignant]] [[lesions]])
|
* [[Adrenal]] [[mass]] or [[nodule]]
* Unilateral or bilateral [[adrenal]] [[atrophy]]
* ↑ [[Fat]]
* Hypodense [[mass]] ([[CT]])
* Iso and low [[FDG]] uptake compared with [[liver]] ([[FDG]] [[PET]]/[[CT]])
* Hyperintense on in-phase and hypointense on oppose-phase ([[MRI]])
|
|
* Diurnal [[plasma]] [[cortisol]] variation
* Diurnal [[plasma]] [[cortisol]] variation
Line 121: Line 121:
* [[Immunohistochemical staining]]
* [[Immunohistochemical staining]]
* [[Dual energy X-ray absorptiometry|Dual-energy X-ray absorptiometry]]
* [[Dual energy X-ray absorptiometry|Dual-energy X-ray absorptiometry]]
|
* [[Adrenal]] [[mass]] or [[nodule]]
* ↑ [[Fat]]
|
* [[Adrenal]] [[mass]] or [[nodule]]
* Unilateral or bilateral [[adrenal]] [[atrophy]]
* ↑ [[Fat]]
* Hypodense [[mass]]
|
* Iso and low [[FDG]] uptake compared with [[liver]]
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
|
* N/A
* N/A
Line 156: Line 168:


*  
*  
|
* Well-defined
* Solid [[mass]]
* Homogeneous enhancement ([[CT]] [[contrast]])
* Hyperintense on in-phase and hypointense on oppose-phase ([[MRI]])
|
|
* [[FSH]], [[LH]], [[prolactin]] levels
* [[FSH]], [[LH]], [[prolactin]] levels
Line 168: Line 174:
* [[Pelvic]] [[Ultrasound]]
* [[Pelvic]] [[Ultrasound]]
* [[Adrenal Venous sampling]]
* [[Adrenal Venous sampling]]
|
* Well-defined
* Solid [[mass]]
|
* Homogeneous enhancement ([[CT]] [[contrast]])
|
* N/A
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
|
* N/A
* N/A
Line 200: Line 215:
* Typically resemble normal [[adrenal]] [[histology]]
* Typically resemble normal [[adrenal]] [[histology]]
* May see [[hemorrhage]] & [[necrosis]]
* May see [[hemorrhage]] & [[necrosis]]
|
* Solid, well defined [[mass]] ([[ultrasound]])
* High [[lipid]] content and adjacent compression ([[CT]])
* Hyperintense on in-phase and hypointense on oppose-phase ([[MRI]])
|
|
* [[Adrenal]] [[hormones]] levels
* [[Adrenal]] [[hormones]] levels
Line 210: Line 221:
* ARR
* ARR
* [[Immunohistochemical staining]]
* [[Immunohistochemical staining]]
|
* Solid, well defined [[mass]]
|
* High [[lipid]] content and adjacent compression
|
* N/A
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
|
* N/A
* N/A
Line 248: Line 267:
* [[Nuclear]] [[pleomorphism]]
* [[Nuclear]] [[pleomorphism]]
* Lymphovascular [[invasion]]
* Lymphovascular [[invasion]]
|
* Heterogeneous enhancement ([[CT]])
* Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted) ([[MRI]])
* Heterogeneous mass with intense [[FDG]] uptake greater than [[liver]] ([<sup>18</sup>F][[FDG]] [[PET]]/[[CT]])
|
|
* [[Serum]] [[ACTH]]
* [[Serum]] [[ACTH]]
Line 259: Line 274:
* [<sup>11</sup>C]MTO [[PET]]
* [<sup>11</sup>C]MTO [[PET]]
* [[Immunohistochemical staining]]
* [[Immunohistochemical staining]]
|
* N/A
|
* Heterogeneous enhancement
|
* Heterogeneous mass with intense [[FDG]] uptake greater than [[liver]]
|
* Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted)
|
|
* N/A
* N/A
Line 308: Line 331:
* [[endocrine]] [[atypia]]
* [[endocrine]] [[atypia]]
* Small [[nodules]]  
* Small [[nodules]]  
|
* [[Adrenal]] [[mass]]
* Unilateral or bilateral [[adrenal]] enlargement or thickening
* [[Density]] and signaling is same as that of normal [[adrenal gland]]
|
|
* [[Adrenal venous sampling]]
* [[Adrenal venous sampling]]
Line 322: Line 341:
* [[FSH]], [[LH]], [[prolactin]] levels
* [[FSH]], [[LH]], [[prolactin]] levels
* [[Cortisol]] levels
* [[Cortisol]] levels
|
* [[Adrenal]] [[mass]]
* Unilateral or bilateral [[adrenal]] enlargement or thickening
|
* Unilateral or bilateral [[adrenal]] enlargement or thickening
* [[Density]] is same as that of normal [[adrenal gland]]
|
* N/A
|
* Unilateral or bilateral [[adrenal]] enlargement or thickening
* Signaling is same as that of normal [[adrenal gland]]
|
|
* N/A
* N/A
Line 332: Line 362:
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
standard
standard
Line 341: Line 371:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Imaging
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
!CT scan
!FDG PET/CT
!MRI
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pheochromocytoma]]<br><ref name="pmid24636754">{{cite journal |vauthors=Martucci VL, Pacak K |title=Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment |journal=Curr Probl Cancer |volume=38 |issue=1 |pages=7–41 |date=2014 |pmid=24636754 |pmc=3992879 |doi=10.1016/j.currproblcancer.2014.01.001 |url=}}</ref><ref name="pmid20541673">{{cite journal |vauthors=Kantorovich V, Pacak K |title=Pheochromocytoma and paraganglioma |journal=Prog. Brain Res. |volume=182 |issue= |pages=343–73 |date=2010 |pmid=20541673 |pmc=4714594 |doi=10.1016/S0079-6123(10)82015-1 |url=}}</ref><ref name="pmid19605896">{{cite journal |vauthors=Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV |title=Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus) |journal=Vet. Pathol. |volume=46 |issue=6 |pages=1221–9 |date=November 2009 |pmid=19605896 |doi=10.1354/vp.09-VP-0022-M-FL |url=}}</ref><ref name="pmid19120142">{{cite journal |vauthors=Kantorovich V, Eisenhofer G, Pacak K |title=Pheochromocytoma: an endocrine stress mimicking disorder |journal=Ann. N. Y. Acad. Sci. |volume=1148 |issue= |pages=462–8 |date=December 2008 |pmid=19120142 |pmc=2693284 |doi=10.1196/annals.1410.081 |url=}}</ref><ref name="pmid25332315">{{cite journal |vauthors=Eisenhofer G, Peitzsch M |title=Laboratory evaluation of pheochromocytoma and paraganglioma |journal=Clin. Chem. |volume=60 |issue=12 |pages=1486–99 |date=December 2014 |pmid=25332315 |doi=10.1373/clinchem.2014.224832 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pheochromocytoma]]<br><ref name="pmid24636754">{{cite journal |vauthors=Martucci VL, Pacak K |title=Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment |journal=Curr Probl Cancer |volume=38 |issue=1 |pages=7–41 |date=2014 |pmid=24636754 |pmc=3992879 |doi=10.1016/j.currproblcancer.2014.01.001 |url=}}</ref><ref name="pmid20541673">{{cite journal |vauthors=Kantorovich V, Pacak K |title=Pheochromocytoma and paraganglioma |journal=Prog. Brain Res. |volume=182 |issue= |pages=343–73 |date=2010 |pmid=20541673 |pmc=4714594 |doi=10.1016/S0079-6123(10)82015-1 |url=}}</ref><ref name="pmid19605896">{{cite journal |vauthors=Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV |title=Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus) |journal=Vet. Pathol. |volume=46 |issue=6 |pages=1221–9 |date=November 2009 |pmid=19605896 |doi=10.1354/vp.09-VP-0022-M-FL |url=}}</ref><ref name="pmid19120142">{{cite journal |vauthors=Kantorovich V, Eisenhofer G, Pacak K |title=Pheochromocytoma: an endocrine stress mimicking disorder |journal=Ann. N. Y. Acad. Sci. |volume=1148 |issue= |pages=462–8 |date=December 2008 |pmid=19120142 |pmc=2693284 |doi=10.1196/annals.1410.081 |url=}}</ref><ref name="pmid25332315">{{cite journal |vauthors=Eisenhofer G, Peitzsch M |title=Laboratory evaluation of pheochromocytoma and paraganglioma |journal=Clin. Chem. |volume=60 |issue=12 |pages=1486–99 |date=December 2014 |pmid=25332315 |doi=10.1373/clinchem.2014.224832 |url=}}</ref>
Line 382: Line 415:
*Scattered [[tumor]] [[cells]] with prominent anisokaryosis, abundant [[eosinophilic]] granular [[cytoplasm]] and indistinct [[cell]] borders
*Scattered [[tumor]] [[cells]] with prominent anisokaryosis, abundant [[eosinophilic]] granular [[cytoplasm]] and indistinct [[cell]] borders
*Occasional bi-nucleate [[cells]]
*Occasional bi-nucleate [[cells]]
|
*Heterogeneous appearance, often with some [[cystic]] areas. [[Calcification]] or [[hemorrhage]] may also be present ([[CT-scans|CT]])
*T2-bright lesions, with/without [[cystic]] or [[necrotic]] components ([[MRI]])
*[[Cystic]] or solid with [[necrotic]] areas or [[hemorrhages]] ([[Ultrasonogram|U/S]])
|
|
*Genetic testing
*Genetic testing
Line 394: Line 422:
*[[PET]] scan
*[[PET]] scan
*[[Octereoscan]]
*[[Octereoscan]]
|
*Heterogeneous appearance, often with some [[cystic]] areas. [[Calcification]] or [[hemorrhage]] may also be present ([[CT-scans|CT]])
*T2-bright lesions, with/without [[cystic]] or [[necrotic]] components ([[MRI]])
*[[Cystic]] or solid with [[necrotic]] areas or [[hemorrhages]] ([[Ultrasonogram|U/S]])
|
|
|
|
|
* [[Plasma]] and [[urine]] [[catecholamines]] & [[metanephrines]] combined with [[clinical]] findings
* [[Plasma]] and [[urine]] [[catecholamines]] & [[metanephrines]] combined with [[clinical]] findings
Line 444: Line 480:
* Salt and pepper [[chromatin]]
* Salt and pepper [[chromatin]]
* [[spindle]]-like [[fibers]]
* [[spindle]]-like [[fibers]]
|
* [[Immunohistochemical staining]]
* [[PET]] scan
*[[Octereoscan]]
*<sup>131</sup>I-metaiodobenzylguanidine (MIBG) [[scintigraphy]]
*[[FISH]]
*[[Genetic testing]]
|
|
* Large mass extending across the midline      ([[CT]])
* Large mass extending across the midline      ([[CT]])
Line 451: Line 494:
* Hypointense (T1-weighted)
* Hypointense (T1-weighted)
|
|
* [[Immunohistochemical staining]]
|
* [[PET]] scan
|
*[[Octereoscan]]
*<sup>131</sup>I-metaiodobenzylguanidine (MIBG) [[scintigraphy]]
*[[FISH]]
*[[Genetic testing]]
|
|
* Pathological examinations
* Pathological examinations
Line 491: Line 530:
* Mature type: mature [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]]
* Mature type: mature [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]]
* Maturing type: [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]] with varying [[maturation]]
* Maturing type: [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]] with varying [[maturation]]
|
* [[Ultrasound]]
* [[Immunohistochemical staining]]
* <sup>18</sup>F-2-fluoro-deoxy-D-glucose-[[positron emission tomography]] ([[PET]])
|
|
* well-defined, Homogeneous ([[CT]])
* well-defined, Homogeneous ([[CT]])
Line 497: Line 540:
* Varied signal (T2-weighted)
* Varied signal (T2-weighted)
|
|
* [[Ultrasound]]
|
* [[Immunohistochemical staining]]
|
* <sup>18</sup>F-2-fluoro-deoxy-D-glucose-[[positron emission tomography]] ([[PET]])
|
|
* Pathological examinations
* Pathological examinations
Line 516: Line 558:
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
|
|
|
|
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
standard
standard
Line 525: Line 571:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Imaging  
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Imaging  
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
!
!
!
|+
|+
|-
|-
Line 547: Line 596:
* [[Hemorrhagic]] foci
* [[Hemorrhagic]] foci
* Islands of [[Hematopoiesis lineages|hematopoietic cells]] ([[myolipoma]]) and mature [[fat cells]] ([[Lipoma]])
* Islands of [[Hematopoiesis lineages|hematopoietic cells]] ([[myolipoma]]) and mature [[fat cells]] ([[Lipoma]])
|
* [[Renal function tests|RFTs]]
* [[LFTs]]
* [[Urinalysis|Urine analysis]]
* [[Ultrasound]]
|
|
* [[Retro-peritoneal]] [[mass]]
* [[Retro-peritoneal]] [[mass]]
Line 552: Line 606:
* High signal ([[MRI]])
* High signal ([[MRI]])
|
|
* [[Renal function tests|RFTs]]
|
* [[LFTs]]
|
* [[Urinalysis|Urine analysis]]
* [[Ultrasound]]
|
|
* Pathological examinations
* Pathological examinations
Line 565: Line 617:
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
|
|
|
|
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold
standard
standard
Line 574: Line 630:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Imaging  
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Imaging  
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
!
!
!
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]]<br><ref name="pmid27006656">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Rendon A, Barrera-Sánchez M, Carlos-Reyna KE, Álvarez-Villalobos NA, González-Saldivar G, González-González JG |title=Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test |journal=Int J Endocrinol |volume=2016 |issue= |pages=9051865 |date=2016 |pmid=27006656 |pmc=4781954 |doi=10.1155/2016/9051865 |url=}}</ref><ref name="pmid15451821">{{cite journal |vauthors=Haddara WM, van Uum SH |title=TB and adrenal insufficiency |journal=CMAJ |volume=171 |issue=7 |pages=710; author reply 710–1 |date=September 2004 |pmid=15451821 |pmc=517840 |doi=10.1503/cmaj.1041046 |url=}}</ref><ref name="pmid26516430">{{cite journal |vauthors=Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW |title=Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status |journal=World J Radiol |volume=7 |issue=10 |pages=336–42 |date=October 2015 |pmid=26516430 |pmc=4620114 |doi=10.4329/wjr.v7.i10.336 |url=}}</ref><ref name="pmid28233510">{{cite journal |vauthors=Vinnard C, Blumberg EA |title=Endocrine and Metabolic Aspects of Tuberculosis |journal=Microbiol Spectr |volume=5 |issue=1 |pages= |date=January 2017 |pmid=28233510 |doi=10.1128/microbiolspec.TNMI7-0035-2016 |url=}}</ref><ref name="pmid23687365">{{cite journal |vauthors=Rajasekharan C, Ajithkumar S, Anto V, Parvathy R |title=Extrapulmonary disseminated tuberculosis with tuberculous adrenalitis: a stitch in time saves nine |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=May 2013 |pmid=23687365 |doi=10.1136/bcr-2012-008011 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]]<br><ref name="pmid27006656">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Rendon A, Barrera-Sánchez M, Carlos-Reyna KE, Álvarez-Villalobos NA, González-Saldivar G, González-González JG |title=Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test |journal=Int J Endocrinol |volume=2016 |issue= |pages=9051865 |date=2016 |pmid=27006656 |pmc=4781954 |doi=10.1155/2016/9051865 |url=}}</ref><ref name="pmid15451821">{{cite journal |vauthors=Haddara WM, van Uum SH |title=TB and adrenal insufficiency |journal=CMAJ |volume=171 |issue=7 |pages=710; author reply 710–1 |date=September 2004 |pmid=15451821 |pmc=517840 |doi=10.1503/cmaj.1041046 |url=}}</ref><ref name="pmid26516430">{{cite journal |vauthors=Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW |title=Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status |journal=World J Radiol |volume=7 |issue=10 |pages=336–42 |date=October 2015 |pmid=26516430 |pmc=4620114 |doi=10.4329/wjr.v7.i10.336 |url=}}</ref><ref name="pmid28233510">{{cite journal |vauthors=Vinnard C, Blumberg EA |title=Endocrine and Metabolic Aspects of Tuberculosis |journal=Microbiol Spectr |volume=5 |issue=1 |pages= |date=January 2017 |pmid=28233510 |doi=10.1128/microbiolspec.TNMI7-0035-2016 |url=}}</ref><ref name="pmid23687365">{{cite journal |vauthors=Rajasekharan C, Ajithkumar S, Anto V, Parvathy R |title=Extrapulmonary disseminated tuberculosis with tuberculous adrenalitis: a stitch in time saves nine |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=May 2013 |pmid=23687365 |doi=10.1136/bcr-2012-008011 |url=}}</ref>
Line 615: Line 674:
* Rim of [[granulomatous]] [[inflammatory cells]] ([[Langerhans giant cells]] and [[lymphocytes]])
* Rim of [[granulomatous]] [[inflammatory cells]] ([[Langerhans giant cells]] and [[lymphocytes]])
* Identifiable [[Acid fast|acid-fast stain]]-positive [[bacteria]] with [[Ziehl-Neelsen stain|Ziehl-Neelsen]] or [[Immunofluorescence|fluorescent stains]]
* Identifiable [[Acid fast|acid-fast stain]]-positive [[bacteria]] with [[Ziehl-Neelsen stain|Ziehl-Neelsen]] or [[Immunofluorescence|fluorescent stains]]
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
* Hypodense areas ([[CT scan]])
* Rim enhancement ([[CT scan]])
* High [[FDG]] uptake by [[adrenal glands]] (18-[[FDG]] [[PET]]/[[CT]])
|
|
* [[Laparoscopic]] [[adrenalectomy]]
* [[Laparoscopic]] [[adrenalectomy]]
Line 629: Line 682:
* [[Insulin]] induced [[hypoglycemia]]
* [[Insulin]] induced [[hypoglycemia]]
* [[Metyrapone]] stimulation tests
* [[Metyrapone]] stimulation tests
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
* Hypodense areas ([[CT scan]])
* Rim enhancement ([[CT scan]])
* High [[FDG]] uptake by [[adrenal glands]] (18-[[FDG]] [[PET]]/[[CT]])
|
|
|
|
|
* N/A
* N/A
Line 675: Line 737:
* ''[[Histoplasma]]'' identification ([[H&E stain]])
* ''[[Histoplasma]]'' identification ([[H&E stain]])
* Focal ovoid bodies with a clear halo ([[PAS stain]])
* Focal ovoid bodies with a clear halo ([[PAS stain]])
|
* [[Laparoscopic]] [[adrenalectomy]]
* [[Endoscopic ultrasound]]
* [[Abdominal ultrasound]]
* [[Chest X-ray]]
* [[ACTH]] stimulation test
* [[Metyrapone]] stimulation tests
|
|
* Enlarged [[adrenal glands]]
* Enlarged [[adrenal glands]]
Line 682: Line 751:
* Abnormal [[FDG]] uptake by [[adrenal glands]] (18-FDG [[PET]]/[[CT]])
* Abnormal [[FDG]] uptake by [[adrenal glands]] (18-FDG [[PET]]/[[CT]])
|
|
* [[Laparoscopic]] [[adrenalectomy]]
|
* [[Endoscopic ultrasound]]
|
* [[Abdominal ultrasound]]
* [[Chest X-ray]]
* [[ACTH]] stimulation test
* [[Metyrapone]] stimulation tests
|
|
* [[Ultrasound]]-guided [[fine needle aspiration]] [[cytology]] ([[Ultrasound|USG]]-[[FNA|FNAC]])
* [[Ultrasound]]-guided [[fine needle aspiration]] [[cytology]] ([[Ultrasound|USG]]-[[FNA|FNAC]])
Line 722: Line 787:
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* [[Hydatid cyst]]: 3 layers (germinal layer, laminated [[membrane]] and dense [[fibrovascular tissue]])
* [[Hydatid cyst]]: 3 layers (germinal layer, laminated [[membrane]] and dense [[fibrovascular tissue]])
|
* Complete [[endocrine]] panel
* [<sup>18</sup>F][[FDG]] [[PET]]/[[CT]] (if [[malignancy]] is suspected)
* [[Biopsy]] (if [[malignancy]] is suspected)
* [[ACTH]] stimulation test
|
|
* Homogeneous [[mass]]
* Homogeneous [[mass]]
Line 730: Line 800:
* Circumscribed anechoic or hypoechoic mass ([[Ultrasound]])
* Circumscribed anechoic or hypoechoic mass ([[Ultrasound]])
|
|
* Complete [[endocrine]] panel
|
* [<sup>18</sup>F][[FDG]] [[PET]]/[[CT]] (if [[malignancy]] is suspected)
|
* [[Biopsy]] (if [[malignancy]] is suspected)
* [[ACTH]] stimulation test
|
|
* [[Ultrasonography]]
* [[Ultrasonography]]
Line 766: Line 834:
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* Findings related to underlying cause
* Findings related to underlying cause
|
* [[Adrenal]] [[ultrasound]]
* [[ACTH]] stimulation test
* Tests related to underlying cause
|
|
* High density (acute [[hemorrhage]] on [[CT]])
* High density (acute [[hemorrhage]] on [[CT]])
Line 771: Line 843:
* Hypointense (Late [[hemorrhage]] on [[MRI]])
* Hypointense (Late [[hemorrhage]] on [[MRI]])
|
|
* [[Adrenal]] [[ultrasound]]
|
* [[ACTH]] stimulation test
|
* Tests related to underlying cause
|
|
* N/A
* N/A
Line 807: Line 878:
* [[Calcification]]
* [[Calcification]]
* [[Hemorrhage]]
* [[Hemorrhage]]
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[FDG]]-[[PET]] scan
* [[Endoscopic ultrasound]]
* Post-[[resection]] [[biopsy]] (if [[malignancy]] is suspected)
|
|
* [[Calcification]]
* [[Calcification]]
Line 814: Line 891:
* Peripheral spotty and centripetal enhancement ([[MRI]])
* Peripheral spotty and centripetal enhancement ([[MRI]])
|
|
* Complete [[endocrine]] panel
|
* [[Ultrasound]]
|
* [[FDG]]-[[PET]] scan
* [[Endoscopic ultrasound]]
* Post-[[resection]] [[biopsy]] (if [[malignancy]] is suspected)
|
|
* [[Histopathology]]
* [[Histopathology]]
Line 855: Line 929:
* May resemble [[anaplastic]] large [[cell]] [[lymphoma]] or [[metastatic]] [[carcinoma]]
* May resemble [[anaplastic]] large [[cell]] [[lymphoma]] or [[metastatic]] [[carcinoma]]
* Abundant [[T-cells]]
* Abundant [[T-cells]]
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[ACTH]] stimulation test
* [[CT]]-guided needle [[biopsy]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
|
* Heterogeneous [[mass]]  
* Heterogeneous [[mass]]  
Line 863: Line 943:
* High intensity (T2-[[MRI]]))
* High intensity (T2-[[MRI]]))
|
|
* Complete [[endocrine]] panel
|
* [[Ultrasound]]
|
* [[ACTH]] stimulation test
* [[CT]]-guided needle [[biopsy]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
|
* [[Histopathology]]
* [[Histopathology]]
Line 900: Line 977:
* Flat [[endothelial cells]]
* Flat [[endothelial cells]]
* Mature [[lymphoid]] aggregates
* Mature [[lymphoid]] aggregates
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[FDG]]-[[PET]] scan
* [[Aspiration]] & [[biopsy]]
|
|
* Well-demarcated
* Well-demarcated
Line 906: Line 988:
* T1 hypointense & T2 hyperintense ([[MRI]])
* T1 hypointense & T2 hyperintense ([[MRI]])
|
|
* Complete [[endocrine]] panel
|
* [[Ultrasound]]
|
* [[FDG]]-[[PET]] scan
* [[Aspiration]] & [[biopsy]]
|
|
* [[Histopathology]]
* [[Histopathology]]
Line 941: Line 1,021:
* [[Necrosis]]
* [[Necrosis]]
* [[Calcification]]
* [[Calcification]]
|
* Complete [[endocrine]] panel
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
* Post-resection [[biopsy]] (if [[malignancy]] is suspected)
|
|
* Heterogeneous  
* Heterogeneous  
Line 949: Line 1,033:
* Mixed signals ([[MRI]])
* Mixed signals ([[MRI]])
|
|
* Complete [[endocrine]] panel
|
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
* Post-resection [[biopsy]] (if [[malignancy]] is suspected)
|
|
* N/A
* N/A
Line 1,006: Line 1,089:
* [[Morphology]] similar to the primary [[tumor]]
* [[Morphology]] similar to the primary [[tumor]]
* Compression and [[atrophy]] of adjacent [[adrenal]] [[tissue]]
* Compression and [[atrophy]] of adjacent [[adrenal]] [[tissue]]
|
* [[Blood]] and [[urine]] lab testing
* Complete [[endocrine]] panel
* [[Imaging]] of [[chest]], [[abdomen]], and [[pelvis]]
* [[Immunohistochemistry]]
* [[Endoscopy]]
* [[MRCP]] & [[ERCP]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
|
* [[Calcification]]
* [[Calcification]]
Line 1,014: Line 1,105:
* Isointense on T1- and T2-weighed [[MRI]]
* Isointense on T1- and T2-weighed [[MRI]]
|
|
* [[Blood]] and [[urine]] lab testing
|
* Complete [[endocrine]] panel
|
* [[Imaging]] of [[chest]], [[abdomen]], and [[pelvis]]
* [[Immunohistochemistry]]
* [[Endoscopy]]
* [[MRCP]] & [[ERCP]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
|
* N/A
* N/A

Revision as of 16:57, 19 February 2019

Abbreviations

ACTH: Adrenocorticotropic hormone, ARR: Aldosterone-renin ratio, CAM: Cellular adhesion molecules, ERCP: Endoscopic retrograde cholangiopancreatography, ESR: Erythrocyte sedimentation rate, CT: Computerized tomography, Fluorescence in situ hybridization, FDG: Fluorodeoxyglucose, FSH: Follicle stimulating hormone, GI: Gastrointestinal, H&E stain: Hematoxylin and eosin stain, LCA: Leukocyte common antigen, LDH: Lactate dehydrogenase, LH: Luteinizing hormone, MEN: Multiple endocrine neoplasia, MRCP: Magnetic resonance cholangiopancreatography, MRI: Magnetic resonance imaging, N/A: Not applicable/Not available, N/L: Normal, PAS stain: Periodic acid–Schiff stain, PET: Position emission tomography, PGP: Protein gene product 9.5, TB: Tuberculosis, U/S: Ultrasound, ZF: Zona fasciculata, ZG: Zona granulosa, ZR: Zona reticularis.

Cortex Product Clinical manifestations Diagnosis Gold

standard

Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Adenoma Aldosterone
[1][2][3][4]
  • Iso and low FDG uptake compared with liver
  • Hyperintense on in-phase and hypointense on oppose-phase
Cortisol
[1][5][6][7]
  • Iso and low FDG uptake compared with liver
  • Hyperintense on in-phase and hypointense on oppose-phase
  • N/A
Androgens
[4][8][9][10]
  • Well-defined
  • Solid mass
  • N/A
  • Hyperintense on in-phase and hypointense on oppose-phase
  • N/A
Non-functional
[1][11][12][13]
  • Solid, well defined mass
  • High lipid content and adjacent compression
  • N/A
  • Hyperintense on in-phase and hypointense on oppose-phase
  • N/A
Carcinoma
[12][14][15][16][17]
  • N/A
  • Heterogeneous enhancement
  • Heterogeneous mass with intense FDG uptake greater than liver
  • Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted)
  • N/A
Hyperplasia
[2][5][4][8][9][15][18][19]
  • N/A
  • Unilateral or bilateral adrenal enlargement or thickening
  • Signaling is same as that of normal adrenal gland
  • N/A
Medulla Product Clinical manifestations Diagnosis Gold

standard

Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Pheochromocytoma
[20][21][22][23][24]
Neuroblastoma
[15][25][26][27]
  • Large mass extending across the midline (CT)
  • Heterogeneous enhancement (CT)
  • Calcification & hemorrhage (CT & MRI)
  • Non-homogeneous and hyperintense (T2-weighted)
  • Hypointense (T1-weighted)
  • Pathological examinations
Stains positive for
Ganglioneuroma
[15][28][29][30]
  • well-defined, Homogeneous (CT)
  • Punctate or discrete calcification (CT)
  • Hypointense (T1-weighted)
  • Varied signal (T2-weighted)
  • Pathological examinations

Stains positive for

Stroma Product Clinical manifestations Diagnosis Gold

standard

Other features
Symptoms Signs Blood & Urine Histopathological Others Imaging
Lipoma/Myolipoma
[15][31][32][33]
  • N/A
  • N/L
  • Pathological examinations
Others Product Clinical manifestations Diagnosis Gold

standard

Other features
Symptoms Signs Blood & Urine Histopathological Others Imaging
Tuberculosis
[34][35][36][37][38]
  • N/A
  • N/A
Histoplasmosis
[39][40][41][42][43]
  • N/A
Cysts
[15][44][45][46]
  • N/A
Hematoma
[15][47][48][49]
  • N/A
  • N/A
  • Majority of the cases in neonantal peiod
  • Majority of the cases caused by trauma
Hemangioma
[15][50][51][52]
  • Majority of the cases diagnosed incidentally
  • Majority of the lesions are non-functional with female pre-dominance
Lymphoma
[15][53][54][55]
  • N/A
Cystic Lymphangioma
[15][56][57][58]
  • N/A
  • N/L
  • Well-demarcated
  • Low-density
  • Calcification
  • T1 hypointense & T2 hyperintense (MRI)
Teratoma
[15][59][60][61]
  • N/A
  • N/L
  • N/A
Metastases
[15][62][63][64][65]
  • Related to the primary tumor

OR

  • Isointense on T1- and T2-weighed MRI
  • N/A

References

  1. 1.0 1.1 1.2 Park JJ, Park BK, Kim CK (June 2016). "Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses". Br J Radiol. 89 (1062): 20151018. doi:10.1259/bjr.20151018. PMC 5258164. PMID 26867466.
  2. 2.0 2.1 Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P (August 2015). "Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas". Mol. Cell. Endocrinol. 411: 146–54. doi:10.1016/j.mce.2015.04.022. PMC 4474471. PMID 25958045.
  3. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD (May 2010). "Laboratory investigation of primary aldosteronism". Clin Biochem Rev. 31 (2): 39–56. PMC 2874431. PMID 20498828.
  4. 4.0 4.1 4.2 Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C (2013). "Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging". J Clin Imaging Sci. 3: 61. doi:10.4103/2156-7514.124088. PMC 3935261. PMID 24605256.
  5. 5.0 5.1 Stratakis CA (2008). "Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)". Endocr Dev. 13: 117–32. doi:10.1159/000134829. PMC 3132884. PMID 18493137.
  6. Zilbermint M, Stratakis CA (June 2015). "Protein kinase A defects and cortisol-producing adrenal tumors". Curr Opin Endocrinol Diabetes Obes. 22 (3): 157–62. doi:10.1097/MED.0000000000000149. PMC 4560837. PMID 25871963.
  7. Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Ren K, Zhang Q, Yu Y, An Z, Chen J, Li J (April 2018). "ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures". BMC Endocr Disord. 18 (1): 22. doi:10.1186/s12902-018-0250-6. PMC 5913873. PMID 29685132.
  8. 8.0 8.1 Arnold DT, Reed JB, Burt K (January 2003). "Evaluation and management of the incidental adrenal mass". Proc (Bayl Univ Med Cent). 16 (1): 7–12. PMC 1200803. PMID 16278716.
  9. 9.0 9.1 Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J (2013). "Pure androgen-secreting adrenal adenoma associated with resistant hypertension". Case Rep Endocrinol. 2013: 356086. doi:10.1155/2013/356086. PMC 3681270. PMID 23819074.
  10. Zhou WB, Chen N, Li CJ (January 2019). "A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman". BMC Endocr Disord. 19 (1): 14. doi:10.1186/s12902-019-0342-y. PMC 6343319. PMID 30674304.
  11. Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (October 2016). ""Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study". Ann. Intern. Med. 165 (8): 533–542. doi:10.7326/M16-0547. PMC 5453639. PMID 27479926.
  12. 12.0 12.1 Nieman LK (September 2010). "Approach to the patient with an adrenal incidentaloma". J. Clin. Endocrinol. Metab. 95 (9): 4106–13. doi:10.1210/jc.2010-0457. PMC 2936073. PMID 20823463.
  13. Li B, Guo Q, Yang H, Guan J (January 2013). "Giant non-functional adrenal adenoma: A case report". Oncol Lett. 5 (1): 378–380. doi:10.3892/ol.2012.978. PMC 3525484. PMID 23255953.
  14. Libé R (2015). "Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment". Front Cell Dev Biol. 3: 45. doi:10.3389/fcell.2015.00045. PMC 4490795. PMID 26191527.
  15. 15.00 15.01 15.02 15.03 15.04 15.05 15.06 15.07 15.08 15.09 15.10 15.11 Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T (September 2018). "CT and MRI of adrenal gland pathologies". Quant Imaging Med Surg. 8 (8): 853–875. doi:10.21037/qims.2018.09.13. PMC 6177362. PMID 30306064.
  16. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD (April 2014). "Adrenocortical carcinoma". Endocr. Rev. 35 (2): 282–326. doi:10.1210/er.2013-1029. PMC 3963263. PMID 24423978.
  17. Wang C, Sun Y, Wu H, Zhao D, Chen J (March 2014). "Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers". Histopathology. 64 (4): 567–76. doi:10.1111/his.12283. PMC 4282325. PMID 24102952.
  18. Michelle M A, Jensen CT, Habra MA, Menias CO, Shaaban AM, Wagner-Bartak NA, Roman-Colon AM, Elsayes KM (November 2017). "Adrenal cortical hyperplasia: diagnostic workup, subtypes, imaging features and mimics". Br J Radiol. 90 (1079): 20170330. doi:10.1259/bjr.20170330. PMC 5963387. PMID 28707538. Vancouver style error: name (help)
  19. Zhang Y, Li H (2015). "Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease". Int J Clin Exp Med. 8 (10): 19311–7. PMC 4694469. PMID 26770569.
  20. Martucci VL, Pacak K (2014). "Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment". Curr Probl Cancer. 38 (1): 7–41. doi:10.1016/j.currproblcancer.2014.01.001. PMC 3992879. PMID 24636754.
  21. Kantorovich V, Pacak K (2010). "Pheochromocytoma and paraganglioma". Prog. Brain Res. 182: 343–73. doi:10.1016/S0079-6123(10)82015-1. PMC 4714594. PMID 20541673.
  22. Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV (November 2009). "Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus)". Vet. Pathol. 46 (6): 1221–9. doi:10.1354/vp.09-VP-0022-M-FL. PMID 19605896.
  23. Kantorovich V, Eisenhofer G, Pacak K (December 2008). "Pheochromocytoma: an endocrine stress mimicking disorder". Ann. N. Y. Acad. Sci. 1148: 462–8. doi:10.1196/annals.1410.081. PMC 2693284. PMID 19120142.
  24. Eisenhofer G, Peitzsch M (December 2014). "Laboratory evaluation of pheochromocytoma and paraganglioma". Clin. Chem. 60 (12): 1486–99. doi:10.1373/clinchem.2014.224832. PMID 25332315.
  25. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG (October 2014). "Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project". J. Clin. Oncol. 32 (28): 3169–76. doi:10.1200/JCO.2014.56.1621. PMC 4171360. PMID 25154816.
  26. Bordbar M, Tasbihi M, Kamfiroozi R, Haghpanah S (2014). "Epidemiological and clinical characteristics of neuroblastoma in southern iran". Iran J Ped Hematol Oncol. 4 (3): 89–96. PMC 4173027. PMID 25254086.
  27. Skoura E, Oikonomopoulos G, Vasileiou S, Kyprianou D, Koumakis G, Datseris IE (2014). "(18)F-FDG-PET/CT, (123)I-MIBG and (99m)Tc-MDP whole-body scans, in detecting recurrence of an adult adrenal neuroblastoma". Hell J Nucl Med. 17 (1): 58–61. doi:10.1967/s002449910116. PMID 24563879.
  28. Mylonas KS, Schizas D, Economopoulos KP (October 2017). "Adrenal ganglioneuroma: What you need to know". World J Clin Cases. 5 (10): 373–377. doi:10.12998/wjcc.v5.i10.373. PMC 5648998. PMID 29085827.
  29. Adas M, Koc B, Adas G, Ozulker F, Aydin T (April 2014). "Ganglioneuroma presenting as an adrenal incidentaloma: a case report". J Med Case Rep. 8: 131. doi:10.1186/1752-1947-8-131. PMC 4031973. PMID 24779851.
  30. Li J, Yang CH, Li LM (April 2013). "Diagnosis and treatment of 29 cases of adrenal ganglioneuroma". Eur Rev Med Pharmacol Sci. 17 (8): 1110–3. PMID 23661526.
  31. Lam KY, Lo CY (September 2001). "Adrenal lipomatous tumours: a 30 year clinicopathological experience at a single institution". J. Clin. Pathol. 54 (9): 707–12. PMC 1731508. PMID 11533079.
  32. Gershuni VM, Bittner JG, Moley JF, Brunt LM (January 2014). "Adrenal myelolipoma: operative indications and outcomes". J Laparoendosc Adv Surg Tech A. 24 (1): 8–12. doi:10.1089/lap.2013.0411. PMC 3931430. PMID 24328509.
  33. Luo J, Chen L, Wen Q, Xu L, Chu S, Wang W, Alnemah MM, Fan S (2015). "Lipoadenoma of the adrenal gland: report of a rare entity and review of literature". Int J Clin Exp Pathol. 8 (8): 9693–7. PMC 4583971. PMID 26464739.
  34. Rodríguez-Gutiérrez R, Rendon A, Barrera-Sánchez M, Carlos-Reyna KE, Álvarez-Villalobos NA, González-Saldivar G, González-González JG (2016). "Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test". Int J Endocrinol. 2016: 9051865. doi:10.1155/2016/9051865. PMC 4781954. PMID 27006656.
  35. Haddara WM, van Uum SH (September 2004). "TB and adrenal insufficiency". CMAJ. 171 (7): 710, author reply 710–1. doi:10.1503/cmaj.1041046. PMC 517840. PMID 15451821.
  36. Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW (October 2015). "Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status". World J Radiol. 7 (10): 336–42. doi:10.4329/wjr.v7.i10.336. PMC 4620114. PMID 26516430.
  37. Vinnard C, Blumberg EA (January 2017). "Endocrine and Metabolic Aspects of Tuberculosis". Microbiol Spectr. 5 (1). doi:10.1128/microbiolspec.TNMI7-0035-2016. PMID 28233510.
  38. Rajasekharan C, Ajithkumar S, Anto V, Parvathy R (May 2013). "Extrapulmonary disseminated tuberculosis with tuberculous adrenalitis: a stitch in time saves nine". BMJ Case Rep. 2013. doi:10.1136/bcr-2012-008011. PMID 23687365.
  39. Rog CJ, Rosen DG, Gannon FH (December 2016). "Bilateral adrenal histoplasmosis in an immunocompetent man from Texas". Med Mycol Case Rep. 14: 4–7. doi:10.1016/j.mmcr.2016.11.006. PMC 5154969. PMID 27995051.
  40. Wahab NA, Mohd R, Zainudin S, Kamaruddin NA (2013). "Adrenal involvement in histoplasmosis". EXCLI J. 12: 1–4. PMC 4817423. PMID 27047312.
  41. May D, Khaled D, Gills J (July 2018). "Unilateral adrenal histoplasmosis". Urol Case Rep. 19: 54–56. doi:10.1016/j.eucr.2018.03.010. PMC 5991316. PMID 29888193.
  42. Gupta RK, Majumdar K, Srivastava S, Varakanahalli S, Saran RK (2018). "Endoscopic Ultrasound-guided Cytodiagnosis of Adrenal Histoplasmosis with Reversible CD4 T-Lymphocytopenia and Jejunal Lymphangiectasia". J Cytol. 35 (2): 110–113. doi:10.4103/JOC.JOC_234_15. PMC 5885598. PMID 29643659.
  43. Padma S, Sreehar S (May 2014). "18F FDG PET/CT identifies unsuspected bilateral adrenal histoplasmosis in an elderly immuno compromised patient". Indian J. Med. Res. 139 (5): 786–7. PMC 4140048. PMID 25027093.
  44. Carsote M, Ghemigian A, Terzea D, Gheorghisan-Galateanu AA, Valea A (2017). "Cystic adrenal lesions: focus on pediatric population (a review)". Clujul Med. 90 (1): 5–12. doi:10.15386/cjmed-677. PMID 28246490.
  45. Słapa RZ, Jakubowski WS, Dobruch-Sobczak K, Kasperlik-Załuska AA (December 2015). "Standards of ultrasound imaging of the adrenal glands". J Ultrason. 15 (63): 377–87. doi:10.15557/JoU.2015.0035. PMC 4710689. PMID 26807295.
  46. Olaoye IO, Adesina MD, Afolayan EA (June 2018). "A giant adrenal cyst with an uncertain preoperative diagnosis causing a dilemma in management". Clin Case Rep. 6 (6): 1074–1076. doi:10.1002/ccr3.1519. PMC 5986023. PMID 29881567.
  47. Hamilton D, Harris MD, Foweraker J, Gresham GA (February 2004). "Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection". J. Clin. Pathol. 57 (2): 208–9. PMC 1770213. PMID 14747454.
  48. Di Serafino M, Severino R, Coppola V, Gioioso M, Rocca R, Lisanti F, Scarano E (September 2017). "Nontraumatic adrenal hemorrhage: the adrenal stress". Radiol Case Rep. 12 (3): 483–487. doi:10.1016/j.radcr.2017.03.020. PMC 5551907. PMID 28828107.
  49. Ierardi AM, Petrillo M, Patella F, Biondetti P, Fumarola EM, Angileri SA, Pesapane F, Pinto A, Dionigi G, Carrafiello G (April 2018). "Interventional radiology of the adrenal glands: current status". Gland Surg. 7 (2): 147–165. doi:10.21037/gs.2018.01.04. PMC 5938278. PMID 29770310.
  50. Alhajri K, Alhasan I, Alzerwi N, Abudaff N (April 2011). "Adrenal haemangioma". BMJ Case Rep. 2011. doi:10.1136/bcr.12.2010.3604. PMC 3079485. PMID 22701011.
  51. Iwamoto G, Shimokihara K, Kawahara T, Takamoto D, Yao M, Teranishi JI, Otani M, Uemura H (2018). "Adrenal Hemangioma: A Case of Retroperitoneal Tumor". Case Rep Med. 2018: 8796327. doi:10.1155/2018/8796327. PMC 5836307. PMID 29560018.
  52. Tarchouli M, Boudhas A, Ratbi MB, Essarghini M, Njoumi N, Sair K, Zentar A (2015). "Giant adrenal hemangioma: Unusual cause of huge abdominal mass". Can Urol Assoc J. 9 (11–12): E834–6. doi:10.5489/cuaj.2967. PMC 4639440. PMID 26600897.
  53. Harada K, Kimura K, Iwamuro M, Terasaka T, Hanayama Y, Kondo E, Hayashi E, Yoshino T, Otsuka F (September 2017). "The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency". Intern. Med. 56 (17): 2261–2269. doi:10.2169/internalmedicine.8216-16. PMC 5635296. PMID 28794358.
  54. Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM (February 2017). "Adrenal lymphoma: presentation, management and prognosis". QJM. 110 (2): 103–109. doi:10.1093/qjmed/hcw174. PMID 27795295.
  55. Karimi F (October 2017). "Primary Adrenal Lymphoma Presenting with Adrenal Failure: A Case Report and Review of the Literature". Int J Endocrinol Metab. 15 (4): e12014. doi:10.5812/ijem.12014. PMC 5750783. PMID 29344029.
  56. Michalopoulos N, Laskou S, Karayannopoulou G, Pavlidis L, Kanellos I (December 2015). "Adrenal Gland Lymphangiomas". Indian J Surg. 77 (Suppl 3): 1334–42. doi:10.1007/s12262-015-1206-y. PMC 4775622. PMID 27011561.
  57. Zhao M, Gu Q, Li C, Yu J, Qi H (2014). "Cystic lymphangioma of adrenal gland: a clinicopathological study of 3 cases and review of literature". Int J Clin Exp Pathol. 7 (8): 5051–6. PMC 4152068. PMID 25197378.
  58. Joliat GR, Melloul E, Djafarrian R, Schmidt S, Fontanella S, Yan P, Demartines N, Halkic N (February 2015). "Cystic lymphangioma of the adrenal gland: report of a case and review of the literature". World J Surg Oncol. 13: 58. doi:10.1186/s12957-015-0490-0. PMC 4335415. PMID 25889625.
  59. Ramakant P, Rana C, Singh KR, Mishra A (2018). "Primary adrenal teratoma: An unusual tumor - Challenges in diagnosis and surgical management". J Postgrad Med. 64 (2): 112–114. doi:10.4103/jpgm.JPGM_588_16. PMC 5954807. PMID 29067922.
  60. Li S, Li H, Ji Z, Yan W, Zhang Y (November 2015). "Primary adrenal teratoma: Clinical characteristics and retroperitoneal laparoscopic resection in five adults". Oncol Lett. 10 (5): 2865–2870. doi:10.3892/ol.2015.3701. PMC 4665718. PMID 26722254.
  61. Zhou L, Pan X, He T, Lai Y, Li W, Hu Y, Ni L, Yang S, Chen Y, Lai Y (October 2018). "Primary adrenal teratoma: A case series and review of the literature". Mol Clin Oncol. 9 (4): 437–442. doi:10.3892/mco.2018.1687. PMC 6125700. PMID 30214733.
  62. Karanikiotis C, Tentes AA, Markakidis S, Vafiadis K (November 2004). "Large bilateral adrenal metastases in non-small cell lung cancer". World J Surg Oncol. 2: 37. doi:10.1186/1477-7819-2-37. PMC 535544. PMID 15541184.
  63. ABRAMS HL, SPIRO R, GOLDSTEIN N (January 1950). "Metastases in carcinoma; analysis of 1000 autopsied cases". Cancer. 3 (1): 74–85. PMID 15405683.
  64. Gerber E, Dinlenc C, Wagner JR (2004). "Laparoscopic adrenalectomy for isolated adrenal metastasis". JSLS. 8 (4): 314–9. PMC 3016821. PMID 15554272.
  65. Vaughan ED (September 1998). "Diagnosis and management of surgical adrenal disorders". Int. J. Urol. 5 (5): 401–17. PMID 9781426.